TABLE 3.
ASSOCIATIONS BETWEEN BIOAVAILABLE TESTOSTERONE AND RIGHT VENTRICULAR MEASURES IN LIMITED AND ADJUSTED MODELS, BY SEX
| Men (n = 1,925) |
Women (n = 1,696) |
|||
|---|---|---|---|---|
| β (95% CI)* | P Value | β (95% CI) | P Value | |
| RVEF, % | ||||
| Limited† | −0.37 (−0.97 to 0.23) | 0.23 | −0.15 (−0.51 to 0.20) | 0.40 |
| Adjusted‡ | −0.36 (−0.95 to 0.24) | 0.25 | −0.01 (−0.38 to 0.36) | 0.97 |
| Adjusted + LVEF | −0.40 (−0.94 to 0.14) | 0.15 | 0.02 (−0.33 to 0.37) | 0.92 |
| RVSV, ml | ||||
| Limited | 1.42 (−0.37 to 3.21) | 0.12 | −0.66 (−1.47 to 0.14) | 0.11 |
| Adjusted | 1.97 (0.20 to 3.73) | 0.03 | −0.04 (−0.88 to 0.79) | 0.92 |
| RV mass, g | ||||
| Limited | 0.40 (0.03 to 0.76) | 0.03 | −0.03 (−0.20 to 0.15) | 0.77 |
| Adjusted | 0.49 (0.13 to 0.85) | 0.01 | 0.08 (−0.10 to 0.26) | 0.38 |
| Adjusted + LV mass | 0.44 (0.10 to 0.77) | 0.01 | 0.04 (−0.13 to 0.21) | 0.66 |
| RVEDV, ml | ||||
| Limited | 2.90 (0.47 to 5.33) | 0.02 | −0.70 (−1.75 to 0.36) | 0.20 |
| Adjusted | 3.71 (1.31 to 6.11) | 0.001 | −0.05 (−1.15 to 1.06) | 0.93 |
| Adjusted + LVEDV | 2.43 (0.64 to 4.21) | 0.01 | 0.13 (−0.69 to 0.94) | 0.78 |
| RVESV, ml | ||||
| Limited | 1.48 (0.26 to 2.70) | 0.02 | −0.03 (−0.55 to 0.49) | 0.91 |
| Adjusted | 1.74 (0.53 to 2.96) | 0.01 | −0.01 (−0.55 to 0.54) | 0.98 |
| Adjusted + LVESV | 1.63 (0.55 to 2.71) | 0.001 | −0.01 (−0.51 to 0.49) | 0.96 |
Definition of abbreviations: CI = confidence interval; LV = left ventricle; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; RV = right ventricle; RVEDV = right ventricular end-diastolic volume; RVEF = right ventricular ejection fraction; RVESV = right ventricular end-systolic volume; RVSV = right ventricular stroke volume.
Per ln(nmol/L) increase in bioavailable testosterone.
Adjusted for age, race/ethnicity, height, weight, waist circumference, and testosterone supplementation (in men).
Adjusted for age, race/ethnicity, height, weight, waist circumference, testosterone supplementation (in men), smoking (status and pack-years), diabetes mellitus, impaired glucose tolerance, hypertension, use of antihypertensive medications, systolic and diastolic blood pressure, cholesterol, high density lipoprotein levels, statin use, intentional exercise, and level of education.